MedElevator
Войти в исследования Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2026
Estimating Risk of Guillain-Barré Syndrome in US Medicare-enrolled Older Adults Following Medically Attended Respiratory Syncytial Virus Disease: A Self-controlled Case Series Analysis.
СтатьяПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Liang Caihua, Judy Jennifer, Chilson Erica L, Kelly Scott P, Liu Qing, Maynard Jason D, De Souza Heidi, Gessner Bradford D, Begier Elizabeth
Аннотация
BACKGROUND: Guillain-Barré syndrome (GBS) is considered a rare complication of viral respiratory infections (eg, influenza, severe acute respiratory syndrome coronavirus 2); however, its association with respiratory syncytial virus (RSV) infection has not been studied. We performed a self-controlled case series analysis to estimate GBS risk following medically attended RSV disease among older adults.
METHODS: We identified adults aged ≥65 years with medically attended RSV disease and incident inpatient GBS using specific International Classification of Diseases (ICD) codes, excluding those with prior GBS, from the US Medicare claims data (2011-2024). Risk period was 1 to 42 days after the RSV disease index date; the control period encompassed -180 to -22 days and 43 to 180 days of RSV disease index date. Conditional Poisson regression estimated RSV-related GBS incidence rate ratios (IRRs), adjusting for seasonality and viral activities. Medicare data policies prohibit cell case counts <11 from being displayed.
RESULTS: Among 452 471 eligible patients with RSV disease, <11 incident GBS cases occurred in the risk period and 34 during the control period. The adjusted IRR for GBS after RSV disease was 2.11 (95% confidence interval, 1.01-4.37), consistent across sensitivity analyses of alternative risk/control periods and after excluding coinfections. The IRR increased to 2.59 (1.17-5.73) after ICD-10 code adoption, with a marked rise among patients aged ≥75 years (3.98 [1.45-10.91]).
CONCLUSIONS: GBS risk increases after RSV disease compared to control periods not temporally adjacent to RSV disease, with an effect particularly evident among patients aged ≥75 years. RSV should be recognized as 1 of the pathogens that may rarely lead to GBS.
METHODS: We identified adults aged ≥65 years with medically attended RSV disease and incident inpatient GBS using specific International Classification of Diseases (ICD) codes, excluding those with prior GBS, from the US Medicare claims data (2011-2024). Risk period was 1 to 42 days after the RSV disease index date; the control period encompassed -180 to -22 days and 43 to 180 days of RSV disease index date. Conditional Poisson regression estimated RSV-related GBS incidence rate ratios (IRRs), adjusting for seasonality and viral activities. Medicare data policies prohibit cell case counts <11 from being displayed.
RESULTS: Among 452 471 eligible patients with RSV disease, <11 incident GBS cases occurred in the risk period and 34 during the control period. The adjusted IRR for GBS after RSV disease was 2.11 (95% confidence interval, 1.01-4.37), consistent across sensitivity analyses of alternative risk/control periods and after excluding coinfections. The IRR increased to 2.59 (1.17-5.73) after ICD-10 code adoption, with a marked rise among patients aged ≥75 years (3.98 [1.45-10.91]).
CONCLUSIONS: GBS risk increases after RSV disease compared to control periods not temporally adjacent to RSV disease, with an effect particularly evident among patients aged ≥75 years. RSV should be recognized as 1 of the pathogens that may rarely lead to GBS.